Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bard buys Californian bulking agent firm Genyx:

This article was originally published in Clinica

Executive Summary

CR Bard has agreed to buy Genyx Medical, a private firm based in Aliso Viejo, California, that makes and markets an alternative treatment to surgery for stress urinary incontinence. For an undisclosed sum, it has acquired the assets related to Uryx, a CE marked bulking agent that is injected into the area surrounding the female urethra to support the urinary sphincter. The product is in late-stage trials in the US and Genyx expects to file for pre-market approval in the first half of this year. Bard already markets a collagen implant, Contigen, to treat the condition.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT060895

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel